Table 1.
Demographic and clinical data combined with therapeutic features of patients with axSpA enrolled in our study.
| Demographic features | Mean ± SD |
|---|---|
| Age (years) | 53.48 ± 9.72 |
| Disease duration (years) | 11.28 ± 9.98 |
| Females/males | 27/12 |
| Clinical features | (%) |
| HLA B27 + | 6/39 (15.38%) |
| Psoriasis | 19/39 (48.71)% |
| Radiographic SpA | 26/39 (66.66%) |
| Peripheral involvement | 31/39 (79.48%) |
| GI tract involvement | 0/39 (0%) |
| Ocular involvement | 4/39 (10.25%) |
| PPD test + | 4/39 (10.25%) |
| QFT + | 4/39 (10.25%) |
| Therapeutic features | (%) |
| Previous anti-TNF failure | 29/39 (74.35%) |
| Use of concomitant GC | 11/39 (28.20%) |
| Use of concomitant DMARDs | 14/39 (35.89%) |
| SCK 150/mg/injection | 17/39 (43.58%) |
| SCK 300/mg/injection | 22/39 (56.41%) |
GC: glucocorticoids; GI: gastrointestinal; HLA: human leukocyte antigen; PPD: purified protein derivative; QFT: quantiFERON-TB; SCK: secukinumab; SD: standard deviation; SpA: spondyloarthritis; TNF: tumour necrosis factor.